Increased plasma concentrations of TMAO, choline, and L-carnitine all have been shown to be associated with the presence and severity of CV disease in rodent models and people, and are independent predictors of adverse cardiac events and mortality. [14] [15] [16] [17] [18] [19] [20] [21] [22] A recent meta-analysis found that patients with higher blood concentrations of TMAO had a pooled relative risk of 1.62 (95% confidence interval [CI]: 1.45-1.80) for major adverse CV events and 1.63 (95% CI: 1.36-1.95) for all-cause mortality. 17 In addition, increased blood choline and L-carnitine concentrations both were associated with increased risk for adverse CV events. 17 These associations all were independent of conventional CV risk factors and renal function.
Although most studies in humans have focused on TMAO in coronary artery disease, TMAO has been shown to be increased in people with congestive heart failure (CHF) resulting from both ischemic and nonischemic heart disease. 19, 21, 22 Results of 2 recent in vitro studies suggest that TMAO's nonvascular adverse effects on the heart could be the result of decreased cardiomyocyte contractility and intracellular calcium flux 23 or impaired myocardial energy metabolism. 24 Alternatively, increased TMAO may not be a cause of CV pathology but may be the result of inflammation associated with CV disease.
The role of TMAO and its dietary precursors has not been reported in dogs with CV disease. Therefore, the aim of our pilot study was to determine if differences in plasma concentrations of TMAO, choline, or L-carnitine exist among dogs with DMVD and CHF, dogs with asymptomatic DMVD, and healthy control dogs. We hypothesized that dogs with DMVD would have higher circulating concentrations of TMAO, choline, and L-carnitine compared to healthy control dogs. In addition, we hypothesized that TMAO, choline, and L-carnitine concentrations would be higher in dogs with DMVD and CHF compared to dogs with asymptomatic DMVD. Dogs were fasted before their study visit for ≥8 hours. Blood (10 mL total) was collected by venipuncture into ethylenediaminetetraacetic acid tubes (9 mL for CBC, TMAO, choline, and carnitine fractions) and a serum separator tube (1 mL for biochemistry profile).
| MATERIALS AND METHODS
The CBC and biochemistry profile were performed immediately to determine eligibility. All other blood was centrifuged within 30 minutes and separated, and plasma was divided into 4 aliquots and frozen at FIGURE 1 The formation of trimethylamine N-oxide (TMAO) from dietary L-carnitine or choline. Bacteria within the gastrointestinal (GI) tract metabolize L-carnitine or choline to trimethylamine, which is then absorbed and converted to TMAO by hepatic flavin monooxygenases (FMOs).
free carnitine ratio (E/F ratio) were measured using a radioenzymatic technique according to a previously published protocol. 29 The amount of choline in each dog's main diet was obtained from the manufacturers on a mg/1000 kcal basis (or obtained on a percentage basis and converted to mg/1000 kcal using the diet's caloric density). The choline content of other components of the diet (eg, treats, table food, and foods to give medications) was not assessed. The amount of L-carnitine in diets was not readily available, and therefore dietary L-carnitine content was not compared among groups.
| Statistical analysis
Data were examined graphically and using Shapiro-Wilk tests.
Normally distributed data are presented as mean AE SD, and skewed data are presented as median (range). Normally distributed data (eg, dietary choline concentrations) were compared among the 3 groups (ie, DMVD/CHF, asymptomatic DMVD, and healthy controls) using ANOVA with Tukey's post hoc tests, and skewed data (eg, plasma TMAO, choline, and L-carnitine fractions) were compared using Kruskal-Wallis tests with Dwass-Steel-Critchlow-Fligner tests for pairwise comparisons. Categorical variables are compared among groups using chi square tests, and Spearman correlation coefficients were used to compare blood analytes and echocardiographic variables, as well as dietary choline. All statistical analyses were performed using a commercial statistical software (Systat 13.0; Systat Software, Inc., San Jose, California), and P ≤ .05 was considered statistically significant. (Table 1) . Age was significantly higher in the DMVD/CHF group compared to the asymptomatic DMVD group, but neither the asymptomatic DMVD and control groups nor the DMVD/CHF and control groups were significantly different from one another. Echocardiographic findings were typical of dogs with DMVD (Table 2 ). Serum creatinine concentration was not significantly different among groups (Table 3) .
Compared to controls, dogs with DMVD/CHF had significantly higher TMAO (P = .02; Figure 2 ), choline (P = .01; Figure 3 ), total L-carnitine (P = .01; Figure 4 ), free carnitine (P = .02), carnitine esters (P = .02), and E/F ratio (P = .009). Compared to dogs with asymptomatic DMVD, dogs with DMVD/CHF had significantly higher TMAO (P = .03; Figure 2 ), total L-carnitine (P = .03; Figure 4 ), carnitine esters (P = .05), and E/F ratio (P = .05). Dogs with asymptomatic DMVD were not significantly different from the controls for any of the analytes (Figures 2-4) . Age was significantly associated with TMAO (r = 0.532, P = .002), total carnitine (r = 0.468, P = .009), and free carnitine (r = 0.444, P = .01). Serum creatinine concentrations were not associated with any of the analytes. 
| DISCUSSION
The finding that dogs with DMVD/CHF have higher TMAO concentrations compared to healthy controls is consistent with studies in human patients with CHF. 16, 21 In addition, TMAO concentrations were higher in dogs with DMVD/CHF compared to those with asymptomatic DMVD, which also is consistent with studies comparing people with CHF to those with asymptomatic heart disease. 16, 22 Various explanations have been postulated for the relationship between TMAO and CV disease, including contributions to cardiorenal dysfunction, influences on cholesterol metabolism, suppression of bile acid synthesis, effects on platelet reactivity, and changes in GI permeability resulting from congestion. [14] [15] [16] [17] [18] [19] 21, 30 It remains unknown whether increases in blood concentrations of TMAO are a cause or effect of worsening CV disease and CHF, but PO supplementation of TMAO and its precursors has been shown to induce atherosclerotic CV disease in rodents. 14, 20 Given the findings of our study, in which no significant difference in TMAO concentrations was found between dogs with asymptomatic DMVD and healthy controls, it is possible that increases in TMAO concentrations were a result of CHF, rather than the underlying DVMD. However, ours was a pilot study with a small number of dogs, and additional research is needed to answer this question.
In addition to higher TMAO concentrations, concentrations of TMAO precursors, L-carnitine, and choline were higher in dogs with DMVD/CHF compared to healthy controls, which also is consistent with studies in people. 16, 31 Furthermore, total carnitine, carnitine esters, and E/F ratio were significantly higher in dogs with DMVD/ CHF compared to those with asymptomatic DMVD. In people, increased carnitine esters and E/F ratio have been shown to be associated with the presence of heart failure, increased risk for worsening heart failure, and CV-related death. [31] [32] [33] In contrast to studies in humans, 16 our results did not show a difference in choline concentrations between dogs with DMVD/CHF and those with asymptomatic DMVD. This finding may be related to the small sample size of our study, to species differences, or to dietary factors.
Dietary habits of humans have been shown to affect not only blood concentrations of choline and L-carnitine but also the capacity to generate TMAO after being subjected to increased PO L-carnitine. 14 In our study, a significant correlation was not found between choline content of the dogs' main diet and plasma choline or TMAO. This finding may be related to our inability to calculate total dietary choline for the dogs, because their diets were comprised of not only a single dog food but sometimes several dog foods, treats, table food, and foods used to administer medications. L-Carnitine content of the diet was even more difficult to obtain from manufacturers because it is not an essential and CV disease in people appears to be dependent on concurrent increases in plasma TMAO concentrations. 14, 15 Although not yet studied in dogs, 1 factor that may influence the relationship between diet and CV disease in humans is the GI microflora. [14] [15] [16] [17] [18] [19] [20] [21] [22] In vivo TMAO production is regulated not only by dietary intake of nutrients such as choline and L-carnitine but also by the composition of an individual's GI bacteria. Several studies have documented an abrupt and significant decrease in TMAO concentrations during antimicrobial administration both in humans and rodents, 14, 15, 21, 38 consistent with a role for GI bacteria in TMAO production. Furthermore, modification of diet can rapidly alter the GI microbiome in people. 39, 40 Therefore, both diet and manipulation of the GI microflora offer potential targets for lowering TMAO concentrations in humans, which in turn could affect the risk of adverse CV events.
However, additional research is necessary to determine whether TMAO truly has a pathogenic role in heart disease in humans and if there is any possible relevance for dogs with DMVD.
Our study had a number of limitations that are important to consider. One limitation is small sample size. Our study was designed as a pilot study, and although significant differences were found among the groups in blood analytes, we did not have adequate statistical power to measure associations for blood analytes with potential confounding factors, such as medications or severity of disease. In addition, blood analytes only were measured at a single time point.
Changes in TMAO over time could provide valuable information.
Larger, prospective studies with multiple time points and long-term follow-up would enable the evaluation of prognostic value and the relationships between concentrations of the various metabolites. In addition, diets were not standardized and we did not measure dietary intake of choline or L-carnitine and were not able to obtain information on dietary concentrations of L-carnitine, which also could have affected the results. Only choline concentrations in the main diet were collected, and the choline content of other components of the diet (eg, treats, table food, and foods used for medication administration)
was not evaluated. In addition, choline content of the diets relied on manufacturers' information, rather than on analysis. 41 Data are presented as mean AE SD. All variables are in centimeters unless otherwise noted. The P-value is for comparison among the 3 groups. Variables with different superscript letters within a row are significantly different from one another. Abbreviations: E/F ratio, carnitine esters to free carnitine ratio; TMAO, trimethylamine N-oxide. Data are presented as mean AE SD for creatinine and median (range) for all other variables. The P-value is for comparison among the 3 groups. Variables with different superscript letters within a row are significantly different from one another.
Although no significant difference was found in age between dogs with asymptomatic DMVD and healthy controls or between DMVD/CHF and controls, dogs with DMVD/CHF were significantly older than dogs with asymptomatic DMVD, which is typical for this disease. In studies of humans, age has been found to be correlated with concentrations of TMAO and its precursors, but the relationship of TMAO with CV disease persists after adjustment for age and other traditional CV risk factors. [14] [15] [16] [17] 19, 21, 22, 31, 33 However, future studies are needed in dogs to identify whether age is a confounding factor in the relationship. Finally, because studies in people consistently show an inverse relationship between renal function and TMAO, [16] [17] [18] 22 more specific measures of renal function in these dogs would have been desirable (eg, glomerular filtration rate). However, our study selected dogs without overt renal dysfunction as part of the inclusion criteria, no difference in serum creatinine concentrations was found among groups, and no significant correlation was identified between TMAO concentrations and serum creatinine concentrations.
Despite these limitations, our results showed that circulating con- 
